Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis

Brien, Sarah; Prescott, P.; Bashir, Nasir Zeeshan; Lewith, H.; Lewith, George

doi:10.1016/j.joca.2008.03.002

Cited by 76 publications

(58 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…First, all drug conditions were compared to surgically equivalent DSMO vehicle control groups. Second, doses of DSMO used for medical treatments (e.g., 2-6 g/kg/20 days; Brien et al 2008), which have sometimes been associated with adverse side effects, are over five orders of magnitude greater than those used here. Third, high doses of DMSO administered to adult rats for long durations have produced little or no evidence of neurotoxic effects (Authier et al 2002).…”

Section: Discussionmentioning

confidence: 86%

Anxiolytic-like effects of somatostatin isoforms SST 14 and SST 28 in two animal models (Rattus norvegicus) after intra-amygdalar and intra-septal microinfusions

2011

View full text Add to dashboard Cite

SST receptors in the septum and amygdala are responsive to both SST 14 and SST 28, but not those in the striatum. Although no obvious differences in the anxiolytic-like effects of the isoforms were detected, quantitative or even qualitative differences in their specific anxiolytic effects may occur in different sub-regions of the septum and amygdala, as has been found for benzodiazepine anxiolytics.

show abstract

Section: Discussionmentioning

confidence: 86%

Anxiolytic-like effects of somatostatin isoforms SST 14 and SST 28 in two animal models (Rattus norvegicus) after intra-amygdalar and intra-septal microinfusions

2011

View full text Add to dashboard Cite

show abstract

“…78 It was also used as a treatment option in osteoarthritis 79 but only with relative efficacy on pain scores. We did not see any effect of DMSO on naïve animal sensitivity behavior regarding toxicity and compared the anti-allodynic of rufinamide with DMSO.…”

Section: Limitations Of the Studymentioning

confidence: 99%

Rufinamide Attenuates Mechanical Allodynia in a Model of Neuropathic Pain in the Mouse and Stabilizes Voltage-gated Sodium Channel Inactivated State

et al. 2013

View full text Add to dashboard Cite

Background: Voltage-gated sodium channels dysregulation is important for hyperexcitability leading to pain persistence. Sodium channel blockers currently used to treat neuropathic pain are poorly tolerated. Getting new molecules to clinical use is laborious. We here propose a drug already marketed as anticonvulsant, rufinamide. Methods: We compared the behavioral effect of rufinamide to amitriptyline using the Spared Nerve Injury neuropathic pain model in mice. We compared the effect of rufinamide on sodium currents using in vitro patch clamp in cells expressing the voltage-gated sodium channel Nav1.7 isoform and on dissociated dorsal root ganglion neurons to amitriptyline and mexiletine. Results: In naive mice, amitriptyline (20 mg/kg) increased withdrawal threshold to mechanical stimulation from 1.3 (0.6-1.9) (median [95% CI]) to 2.3 g (2.2-2.5) and latency of withdrawal to heat stimulation from 13.1 (10.4-15.5) to 30.0 s (21.8-31.9), whereas rufinamide had no effect. Rufinamide and amitriptyline alleviated injury-induced mechanical allodynia for 4 h (maximal effect: 0.10 ± 0.03 g (mean ± SD) to 1.99 ± 0.26 g for rufinamide and 0.25 ± 0.22 g to 1.92 ± 0.85 g for amitriptyline). All drugs reduced peak current and stabilized the inactivated state of voltage-gated sodium channel Nav1.7, with similar effects in dorsal root ganglion neurons. Conclusions: At doses alleviating neuropathic pain, amitriptyline showed alteration of behavioral response possibly related to either alteration of basal pain sensitivity or sedative effect or both. Side-effects and drug tolerance/compliance are major problems with drugs such as amitriptyline. Rufinamide seems to have a better tolerability profile and could be a new alternative to explore for the treatment of neuropathic pain. P AIN is essential for survival as it serves as an alert to engage protective behavior. Neuropathic pain, caused by a lesion or disease of the somatosensory nervous system, affects 7% of the population 1 and possesses no protective purpose. Sodium channels are major targets for the development of new drug to treat neuropathic pain.2 Nerve injury changes the expression of sodium channels 3 which affects peripheral nerve hyperexcitability and ectopic discharges along the nerve, in the dorsal root ganglion or at the injury site.4,5 They are composed of a α-pore forming subunit associated to one or two β-modulating subunits. Nine genes encode for the α-subunits, Nav1.1-1.9. Current therapy for neuropathic pain involves adjuvant medications-not primarily developed for this purposesuch as anticonvulsants, antidepressants, or local anesthetics. Address correspondence to Dr. Suter: Pain Center, Department of Anesthesiology, CHUV, Avenue du Bugnon 46, 1011 Lausanne, Switzerland. marc.suter@chuv.ch. Information on purchasing reprints may be found at www.anesthesiology.org or on the masthead page at the beginning of this issue. ANESTHESIOLOGY's articles are made freely accessible to all readers, for personal use only, 6 months from the cover date of the issue.

show abstract

“…9 Apart from the above-described systemic applications, the efficacy of sulfur in the local treatment of arthrtitic disease has been amply described in experiences of bathing patients in mineral sulfate-bicarbonate-calcium water. 32 The pharmacological and clinical properties of Boswellia extract have recently undergone a systematic study.…”

Section: Use Of Anti-inflammatory Drugsmentioning

confidence: 99%

The “MESACA” study: Methylsulfonylmethane and boswellic acids in the treatment of gonarthrosis

Notarnicola¹,

Tafuri

Fusaro³

et al. 2011

Adv Therapy

View full text Add to dashboard Cite

show abstract

Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis

Cited by 76 publications

References 40 publications

Anxiolytic-like effects of somatostatin isoforms SST 14 and SST 28 in two animal models (Rattus norvegicus) after intra-amygdalar and intra-septal microinfusions

Anxiolytic-like effects of somatostatin isoforms SST 14 and SST 28 in two animal models (Rattus norvegicus) after intra-amygdalar and intra-septal microinfusions

Rufinamide Attenuates Mechanical Allodynia in a Model of Neuropathic Pain in the Mouse and Stabilizes Voltage-gated Sodium Channel Inactivated State

The “MESACA” study: Methylsulfonylmethane and boswellic acids in the treatment of gonarthrosis

Contact Info

Product

Resources

About